A, T-tau level, P-tau level, and P-tau–T-tau ratio in plasma of patients with TBI of different severity (Glasgow Coma Scale [GCS] score: mild, 13-15 [n = 160]; moderate, 9-12 [n = 6]; and severe, 3-8 [n = 12]) vs healthy control plasma (n = 20). Median and first and third quartiles are shown (black bars). Statistical significance was based on Kruskal-Wallis test comparison. Mann-Whitney test multiple group comparison results are given in eTable 2 in the Supplement. B, Receiver operating characteristic (ROC) curve of plasma T-tau level, P-tau level, and P-tau–T-tau ratio for all acute TBI (n = 195) vs control (n = 20) samples. C, ROC of T-tau level, P-tau level, and P-tau–T-tau ratio of all patients with acute mild TBI (n = 162) vs controls (n = 20). D, ROC curve of acute plasma T-tau level, P-tau level, and P-tau–T-tau ratio in distinguishing patients with TBI with GCS scores of 13 to 15 vs those with GCS scores of 12 or lower. Detailed characterization analysis of ROC curves is available in eTables 3 and 4 in the Supplement.
T-tau level (A), P-tau level (B), and P-tau–T-tau ratio (C) for CT− (n = 105) and CT+ (n = 91) patients. Median and first and third quartiles are shown (black bars). The receiver operating characteristic (ROC) curve is for T-tau level, P-tau level, and P-tau–T-tau ratio in distinguishing CT+ vs CT– (D). eTable 5 in the Supplement provides detailed characterization. Error bars indicate SE. P values based on Mann-Whitney test comparison.
T-tau level (A), P-tau level (B), and P-tau–T-tau ratio, Glascow Outcome Scale-Extended (GOS-E) of 7 to 8 (good outcome) vs GOS-E of 6 or lower (poor outcome). Median and first and third quartiles are shown (black bars). Statistical significance was based on Mann-Whitney test comparison. Receiver operating characteristic (ROC) curves for T-tau level, P-tau level, and P-tau–T-tau ratio in distinguishing ROC curves for good outcome GOS-E of 7 to 8 vs GOS-E of 6 or lower (D), and ROC curves for poor outcome GOS-E of 4 or lower vs GOS-E of 5 to 8 (E). eTable 6 in the Supplement provides detailed analysis.
A, T-tau level, P-tau, and P-tau–T-tau ratio. Median and first and third quartiles are shown (black bars). Statistical significance was based on Mann-Whitney test comparison; for the 2 subgroups (control vs chronic TBI), T-tau level (P = .02), P-tau level (P < .001), and P-tau–T-tau ratio (P < .001) are significantly different. B, Receiver operating characteristic (ROC) curve of plasma T-tau level, P-tau level, and P-tau–T-tau ratio for patients with chronic TBI vs healthy controls. eTable 7 in the Supplement provides detailed ROC analysis.
eMethods. Detailed Methodology
eFigure 1. Standard Curve for T-Tau Assay (a-EIMAF)
eFigure 2. Standard Curve for P-Tau (T231) Assay (a-EIMAF)
eFigure 3. Comparison of Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio in Acute TBI (CT+, CT-) vs Normal Controls
eFigure 4. Comparison of Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio in Acute TBI With Different Marshall CT Finding Scores
eTable 1. Acute Plasma P-Tau, T-Tau Levels and P-Tau/T-Tau Ratio in TBI Patients From Different GCS Severity Categories and Normal Control
eTable 2. Comparing Acute Plasma P-Tau, T-Tau, P-Tau/T-Tau Ratio in TBI Patients From Different GCS Severity Category and Normal Control by Mann-Whitney U-Test Multiple Comparisons
eTable 3. Acute Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio ROC Curve Characterization for All TBI vs Control and Mtbi vs Control
eTable 4. Acute Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio ROC Curve Characterization for GCS 13-15 vs GCS≤12
eTable 5. Acute Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio ROC Curve Characterization for CT+ vs CT-
eTable 6. Acute Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio ROC Curve Characterization for Predicting Patient Outcome at 6 mo. (GOS-E)
eTable 7. Plasma P-Tau, T-Tau and P-Tau/T-Tau Ratio ROC Curve Characterization for Chronic TBI Subjects vs Normal Control
Customize your JAMA Network experience by selecting one or more topics from the list below.
Rubenstein R, Chang B, Yue JK, et al. Comparing Plasma Phospho Tau, Total Tau, and Phospho Tau–Total Tau Ratio as Acute and Chronic Traumatic Brain Injury Biomarkers. JAMA Neurol. 2017;74(9):1063–1072. doi:10.1001/jamaneurol.2017.0655
What is the association between plasma phospho-tau and total-tau levels and traumatic brain injury presence, severity, type of pathoanatomic lesions, and patient outcome?
In a cohort study, plasma samples from the TRACK-TBI pilot study were collected at a single time point from 196 patients with acute traumatic brain injury and 21 patients with severe traumatic brain injury admitted to receive inpatient rehabilitation. Plasma phospho-tau levels and phospho tau–total tau ratio during the acute phase and chronic traumatic brain injury were superior to total-tau levels for discriminating the severity and status of neurotrauma patients from healthy controls.
Plasma phospho-tau levels and phospho tau–total tau ratio might be useful diagnostic and prognostic biomarkers for both acute and chronic traumatic brain injury.
Annually in the United States, at least 3.5 million people seek medical attention for traumatic brain injury (TBI). The development of therapies for TBI is limited by the absence of diagnostic and prognostic biomarkers. Microtubule-associated protein tau is an axonal phosphoprotein. To date, the presence of the hypophosphorylated tau protein (P-tau) in plasma from patients with acute TBI and chronic TBI has not been investigated.
To examine the associations between plasma P-tau and total-tau (T-tau) levels and injury presence, severity, type of pathoanatomic lesion (neuroimaging), and patient outcomes in acute and chronic TBI.
Design, Setting, and Participants
In the TRACK-TBI Pilot study, plasma was collected at a single time point from 196 patients with acute TBI admitted to 3 level I trauma centers (<24 hours after injury) and 21 patients with TBI admitted to inpatient rehabilitation units (mean [SD], 176.4 [44.5] days after injury). Control samples were purchased from a commercial vendor. The TRACK-TBI Pilot study was conducted from April 1, 2010, to June 30, 2012. Data analysis for the current investigation was performed from August 1, 2015, to March 13, 2017.
Main Outcomes and Measures
Plasma samples were assayed for P-tau (using an antibody that specifically recognizes phosphothreonine-231) and T-tau using ultra-high sensitivity laser-based immunoassay multi-arrayed fiberoptics conjugated with rolling circle amplification.
In the 217 patients with TBI, 161 (74.2%) were men; mean (SD) age was 42.5 (18.1) years. The P-tau and T-tau levels and P-tau–T-tau ratio in patients with acute TBI were higher than those in healthy controls. Receiver operating characteristic analysis for the 3 tau indices demonstrated accuracy with area under the curve (AUC) of 1.000, 0.916, and 1.000, respectively, for discriminating mild TBI (Glasgow Coma Scale [GCS] score, 13-15, n = 162) from healthy controls. The P-tau level and P-tau–T-tau ratio were higher in individuals with more severe TBI (GCS, ≤12 vs 13-15). The P-tau level and P-tau–T-tau ratio outperformed the T-tau level in distinguishing cranial computed tomography–positive from -negative cases (AUC = 0.921, 0.923, and 0.646, respectively). Acute P-tau levels and P-tau–T-tau ratio weakly distinguished patients with TBI who had good outcomes (Glasgow Outcome Scale–Extended GOS-E, 7-8) (AUC = 0.663 and 0.658, respectively) and identified those with poor outcomes (GOS-E, ≤4 vs >4) (AUC = 0.771 and 0.777, respectively). Plasma samples from patients with chronic TBI also showed elevated P-tau levels and a P-tau–T-tau ratio significantly higher than that of healthy controls, with both P-tau indices strongly discriminating patients with chronic TBI from healthy controls (AUC = 1.000 and 0.963, respectively).
Conclusions and Relevance
Plasma P-tau levels and P-tau–T-tau ratio outperformed T-tau level as diagnostic and prognostic biomarkers for acute TBI. Compared with T-tau levels alone, P-tau levels and P-tau–T-tau ratios show more robust and sustained elevations among patients with chronic TBI.
Traumatic brain injury (TBI), considered as an event and/or a disease, initiates a complex pathophysiologic central nervous system cascade with acute effects and secondary insults that may lead to chronic functional, neurocognitive, and neuropsychiatric deficits.1 Traumatic brain injury is classified according to its degree of severity (mild, moderate, and severe). In the United States, there are more than 3.5 million emergency department visits for TBI and more than 280 000 patients are hospitalized annually with TBI, with most of these classified as mild TBI (mTBI). There are also many more individuals with mTBI who never seek medical attention. More than 300 000 armed service members sustained TBI during combat and training from 2000 to 2014.2 Approximately half of patients with TBI in the United States incur at least some short-term disability.3 Traumatic brain injury is associated with an increased risk of neurodegenerative disorders, such as Alzheimer disease, years or decades after injury.4 In addition, repetitive mTBI is a risk factor for a neurodegenerative condition called chronic traumatic encephalopathy (CTE).5-7 Chronic traumatic encephalopathy, which can be confirmed only by postmortem neuropathologic examination, is defined by the abnormal accumulation of hyperphosphorylated tau protein (P-tau) in neurons, astroglia, and cell processes distributed around small blood vessels at the depth of cortical sulci in an irregular pattern.8
Tau protein is involved in regulating axonal microtubule assembly and disassembly. Posttranslational modifications of tau seem to precede brain tauopathy. These modifications include (1) hyperphosphorylation by multiple kinases,9 (2) proteolysis by calpain and caspase,10-12 and (3) oxidative modifications.13-15 The abnormal P-tau protein forms paired helical filaments and progressively aggregates to form the main component of neurofibrillary tangles—a hallmark of tauopathy, including Alzheimer disease.16 The major pathologic P-tau sites include, but are not limited to, threonine (Thr)181, serine (Ser)202, Thr205, Thr231, Ser396, and Ser404.17 Abnormal accumulation of P-tau deposits in postmortem human brains are found years after repetitive mTBIs have been sustained.18,19 Single, simulated blast exposure and closed head injury in mice also result in increased deposition of P-tau.20,21 Amyloid β1-42 and/or tau levels are elevated in cerebrospinal fluid samples after severe TBI.22-24 The use of a high-sensitivity assay platform (Simoa; Quanterix Corp) has permitted detection of acute and chronic tau elevations following mTBI in ice hockey players with sports-related concussion and military personnel with chronic postconcussive disorder symptoms.25,26 In contrast to the present report, those studies did not measure P-tau levels.
We recently used another high-sensitivity assay platform (multi-arrayed fiberoptics conjugated with rolling circle amplification [a-EIMAF]) and detected serum total (T)-tau and P-tau levels in patients with severe TBI,27 as well as in 1- to 30-day mouse serum after single and/or repetitive mTBI.21 However, to our knowledge, the profile of P-tau in blood samples in humans with mild and moderate TBI has yet to be defined. Incorporating the 3 tau indices to distinguish abnormal cranial computed tomography (CT) (pathoanatomic lesions) from normal CT findings would aid in the diagnosis and prognosis for acute TBI. Furthermore, to our knowledge, monitoring the 3 tau indices simultaneously in blood samples from patients with chronic TBI has not been done previously. Therefore, we used the a-EIMAF platform to examine whether P-tau and T-tau might be sensitive and specific biomarkers, using plasma from patient cohorts in the completed TRACK-TBI Pilot study.
Four sites (3 level I trauma centers and 1 rehabilitation center) participated in this study. On arrival, participants were classified along the spectrum of neurotrauma severity (Glasgow Coma Scale [GCS)] score of 3-8, severe; 9-12, moderate; and 13-15, mild) and recruited into the multicenter, prospective TRACK-TBI Pilot study.28 The TRACK-TBI Pilot study was conducted from April 1, 2010, to June 30, 2012. Data analysis for the current investigation was performed from August 1, 2015, to March 13, 2017.
Study protocols were approved by the institutional review boards of participating centers (acute sites: San Francisco General Hospital, San Francisco, California; University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; and University Medical Center Brackenridge, Austin, Texas; rehabilitation site: Mount Sinai Rehabilitation Center, New York). Participants or their legally authorized representative provided written informed consent.
Patients with acute TBI must have presented within 24 hours of injury to the emergency department and have had a noncontrast head CT scan performed based on American College of Emergency Physicians/Centers for Disease Control and Prevention guidelines29; patients with chronic TBI must have had sufficient neurologic impairment to be admitted to inpatient TBI rehabilitation units.30 Single blood samples from patients with acute TBI across the full spectrum of injury severity (GCS, 3-8 [n = 25]; GCS, 9-12 [n = 8]; and GCS, 13-15 [n = 163]) were collected within 24 hours of injury. Among these patients with acute TBI, 108 (55.1%) had normal head CT (CT−) scans, while 88 (44.9%) showed CT abnormality (CT+) (Table). Single blood samples from 21 patients with chronic TBI were collected during the inpatient rehabilitation stay (Table).30 Sample collection and processing for the TBI and healthy control cohorts were performed identically at all sites (including the commercial vendor for controls) according to the recommendations from the National Institutes of Health–National Institute of Neurological Disorders and Stroke Common Data Elements Biospecimens and Biomarkers Working Group31 (eMethods in the Supplement provides details). Plasma was extracted after centrifugation of whole blood collected in K2-EDTA blood tubes for 5 minutes at 3000g. In addition, 20 commercially obtained samples (Bioreclamation Inc) from healthy control plasma (K2-EDTA tubes) (n = 20; mean [SD] age, 40.5 [14.2] years; 70% male), which were sex- and age-matched with the acute (n = 196; age, 42.1 [18.1] years; 73% male) and chronic (n = 21; age, 44.4 [20.5] years; 76% male) TBI samples, were assayed. There were no significant differences in age or sex across the patient and control cohorts (Table). In the 217 patients with TBI, 161 (74.2%) were men; mean age was 42.5 (18.1) years.
T-tau and P-tau a-EIMAF assay performance, lower limit of detection, lower limit of quantitation, and linearity range of standard curves for calculating T-tau and P-tau concentration are shown in eFigures 1 and 2 in the Supplement, respectively (eMethods in the Supplement).
The T-tau and P-tau data for the acute and chronic TBI cohorts and controls were not normally distributed; thus, results are presented as median and interquartile range. Median differences for more than 2 groups were compared with the Kruskal-Wallis test. For 2-group comparisons, the nonparametric Mann-Whitney test was performed. The ability of T-tau level, P-tau level, and P-tau–T-tau ratio to distinguish patients with acute TBI vs controls, mild (GCS, 13-15) vs moderate/severe (GCS, 3-12) TBI, normal vs abnormal cranial CT, 6-month outcomes on Glasgow Outcome Scale–Extended (GOS-E), and chronic TBI vs controls were assessed using the receiver operating characteristic (ROC) curve and associated area under the curve (AUC). Statistical analyses were performed using Prism, version 6 (GraphPad Software). Statistical significance was defined by an unpaired, 2-tailed P value ≤.05.
Plasma P-tau levels, T-tau levels, and P-tau–T-tau ratios were determined for all patients with acute and chronic TBI. We have previously described detection of T-tau and P-tau in cerebrospinal fluid (EIMAF format) and serum (a-EIMAF format) from patients with severe TBI during the first 5 days after injury.28 Herein, we expand these findings by using plasma samples from 2 cohorts of the TRACK-TBI Pilot study and quantitate concentrations of T-tau and P-tau (eFigure 1 and eFigure 2 in the Supplement).
In controls, we found no significant correlations between any of the 3 tau indices and age. For CT− patients, age had statistically significant Pearson correlation coefficients with P-tau level (r = 0.200, P = .04) and P-tau–T-tau ratio (r = 0.233, P = .02), but not with T-tau level (r = −0.075, P = .45). For CT+ patients, age had a statistically significant Pearson correlation coefficient with P-tau–T-tau ratio (r = 0.219, P = .04), but not for P-tau (r = 0.157, P = .14) or T-tau (r = −0.082, P = .44) levels.
Plasma values of T-tau were 62.59 fg/mL for healthy controls, 79.21 fg/mL for patients with acute TBI with initial GCS 13 to 15, 84.10 fg/mL for GCS 9 to 12, and 79.21 for GCS 3 to 8 (P < .001 across groups) (Figure 1A, eTable 1 in the Supplement). Median P-tau level was 20.85 fg/mL × 100 for healthy controls, 200.16 fg/mL × 100 for patients with acute TBI with GCS 13 to 15, 307.19 fg/mL × 100 for GCS 9 to 12, and 294.68 fg/mL × 100 for GCS 3 to 8 (P < .001) (Figure 1A, eTable 1 in the Supplement). P-tau–T-tau ratio ( × 10 000) for healthy controls was 30.94, compared with 263.19 for patients with acute TBI with GCS 13 to 15, 348.38 for GCS 9 to12, and 363.02 for GCS 3 to 8 (P < .001) (Figure 1A, eTable 1 in the Supplement). Healthy controls compared with each severity group were significantly different for T-tau level, P-tau level, and P-tau–T-tau ratio (eTable 2 in the Supplement). P-tau values for GCS 13 to 15 vs GCS 9 to 12 and GCS 13 to 15 vs GCS 3 to 8 were significantly different, as were P-tau–T-tau ratios for GCS 13 to 15 vs GCS 3 to 8 (eTable 2 in the Supplement).
The ROC analyses showed the accuracy of all 3 plasma tau indices in distinguishing all acute TBI cases from healthy controls (Figure 1B). The AUC was 0.919 (P < .001) for T-tau level, 1.000 (P < .001) for P-tau level, and 1.000 (P < .001) for P-tau–T-tau ratio (eTable 3 in the Supplement, all TBI vs controls). All 3 plasma tau indices also showed accuracy in distinguishing mTBI (GCS 13-15) from normal control plasma (Figure 1C), with AUC = 0.916 (P < .001) for T-tau level, 1.000 (P < .001) for P-tau level, and 1.000 (P < .001) for P-tau–T-tau (eTable 3 in the Supplement, mTBI vs controls).
Because our results suggested that P-tau indices could distinguish mTBI (GCS 13-15) from severe and moderate TBI (eTable 2 in the Supplement), we further applied ROC plots (Figure 1D). Plasma P-tau levels and P-tau–T-tau ratio showed fair accuracy for distinguishing mTBI (initial GCS 13-15) in patients with severe/moderate TBI (GCS≤12) (AUC = 0.711 and 0.748, respectively; both P < .001), whereas T-tau showed poor, but significant results (AUC 0.527, P = .04) (Figure 1D; eTable 4 in the Supplement).
Neuroimaging using CT assessed the extent of the TBI, thereby allowing pathoanatomic classification. We assessed the ability of the 3 plasma tau indices to distinguish CT+ scan patients with TBI from those with normal findings on scans (CT–). As displayed in Figure 2A-C, median T-tau levels were 78.24 fg/mL for CT– and 83.13 fg/mL for CT+ scans (P < .001) (Figure 2A). P-tau levels were 1.45 fg/mL for CT– and 3.02 fg/mL for CT+ scans (P < .001) (Figure 2B), and the P-tau–T-tau ratio had a median of 0.0187 for CT– and 0.0363 for CT+ scans (P < .001) (Figure 2C). We also performed ROC analysis of 3 tau indices in distinguishing CT+ from CT– scans (Figure 2D). Both P-tau level and P-tau–T-tau ratio had excellent accuracy (AUC = 0.921 and 0.923, respectively), while T-tau had poor accuracy (AUC = 0.646) (eTable 5 in the Supplement).
We compared the acute TBI tau indices of the mTBI (GCS 13-15) groups that had scans that were either CT+ (n = 61) or CT− (n = 102) with those of healthy controls (n = 20) (eFigure 3 in the Supplement). We identified significant group differences for T-tau level, P-tau level, and P-tau–T-tau ratio. Healthy controls could be distinguished from both CT+ and CT− cases based on all 3 tau indices (eFigure 3 in the Supplement). Furthermore, P-tau levels and P-tau–T-tau ratio could distinguish CT+ vs CT− scans among all patients with mTBI, although T-tau levels could not (eFigure 3 in the Supplement).
Finally, we investigated the correlation between acute TBI plasma tau indices and the Marshall CT scale. Owing to small individual counts, the more severe Marshall CT classifications (3-6) were grouped into a single category similar to previous approaches.32-34 Marshall group comparisons showed statistical significance for all 3 tau indices (all P < .001) (eFigure 4 in the Supplement). We also found significant subgroup differences in Marshall CT scores: (1) T-tau level, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .05); (2) P-tau level, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .001); and P-tau–T-tau ratio, 1 vs 2 (P < .001) and 1 vs 3 or higher (P < .001) (eFigure 4 in the Supplement).
Since P-tau might be related to tauopathy formation, we examined the ability of the plasma tau indices to predict outcome in patients with TBI using the GOS-E. Six-month outcome data were available in 137 patients (69.9%), 134 of whom had available plasma samples (68.3%) (Table). A GOS-E score of 7 to 8 is considered a good outcome, and a GOS-E score of 6 or lower is considered a poor outcome. Figure 3B and C demonstrate that both acute TBI plasma P-tau level and P-tau–T-tau ratio have an inverse association with GOS-E. P-tau level (P = .001) and P-tau–T-tau ratio (P = .002) are lower in patients with TBI with a GOS-E of 7 to 8 vs those with a GOS-E of 6 or lower. In contrast, T-tau did not differ significantly between the 2 outcome groups (P = .27) (Figure 3A). In the good outcome (GOS-E, 7-8) column for P-tau level and P-tau–T-tau ratio, there appear to be 2 clusters (above or below 2 fg/mL P-tau level; and above or below 0.025 P-tau–T-tau ratio, respectively). These upper clusters closely match the respective ranges of P-tau level and P-tau–T-tau ratio for the poor outcome group (GOS-E, ≤6). This finding may suggest a natural clustering of acute post-TBI P-tau levels that are independent of our patient outcome measures (eg, GOS-E). In ROC curves for GOS-E of 7 to 8 (good outcome) vs GOS-E of 6 or lower (Figure 3D), the AUC for P-tau level (0.663) and P-tau–T-tau ratio (0.658) show that they are poor predictors of good outcome (eTable 6 in the Supplement, panel A). T-tau level failed to discriminate between those with good outcome (AUC = 0.552). In ROC curves for GOS-E of 4 or lower (poor outcome) vs GOS-E higher than 4 (Figure 3E), AUC for P-tau level (0.771) and for P-tau–T-tau ratio (0.777) shows that both of these P-tau indices are fair predictors of poor outcome (eTable 6 in the Supplement, panel B). The AUC for T-tau level (0.516) was again not significant.
For the chronic TBI cohort, the mean (SD) postinjury time at enrollment was 176.4 (44.5) days (range, 16.0-249.6 days). The plasma T-tau level, P-tau level, and P-tau–T-tau ratio were compared with those of healthy controls (n = 20) (Figure 4A). Median plasma T-tau level for chronic TBI was 69.48 vs 62.59 fg/mL for controls (P = .02); P-tau level was 97.30 fg/mL × 100 for chronic TBI vs 20.85 fg/mL × 100 for controls (P < .001); and the P-tau–T-tau ratio ( × 10 000) was 140.33 for chronic TBI vs 30.95 for controls (P < .001).
Finally, we performed ROC curves of plasma T-tau level, P-tau level, and P-tau–T-tau ratio from patients with chronic TBI vs healthy controls (Figure 4B). P-tau level (AUC = 1.000) and P-tau–T-tau ratio (AUC = 0.963) showed accuracy and outperformed T-tau level (AUC = 0.674) (eTable 7 in the Supplement).
Biomarkers are emerging diagnostic tools for TBI. Since P-tau is pathologically linked to tauopathy found in Alzheimer disease, CTE, and other neurodegenerative diseases associated with TBI,7,18,20 we examined peripheral T-tau and P-tau levels in the full spectrum of patients with TBI by using TRACK-TBI Pilot cohorts.28,30,35 We demonstrate that plasma P-tau (P-Thr231) level, T-tau level, and P-tau–T-tau ratio are robustly higher in patients with all severities of acute TBI compared with healthy controls (Figure 1A). However, both P-tau indices differed according to TBI severity (Figure 1D). Although all patients with TBI and cranial CT+ scans had higher levels of all 3 tau indices than their CT− counterparts, P-tau levels and P-tau–T-tau ratio were much higher and predicted CT scan abnormality more accurately than did T-tau levels (Figure 2). In patients with acute TBI, P-tau levels and P-tau–T-tau ratio outperformed T-tau level in identifying and possibly predicting good outcomes (Figure 3). Taken together, to our knowledge, this is the first report showing that acute plasma P-tau levels and the P-tau–T-tau ratio are superior diagnostic biomarkers for TBI than T-tau levels. Because of the likely differences in T-tau antigen standards and antibodies used in the different assay formats, making direct comparisons between the absolute plasma T-tau values from the acute mild and chronic TBI cohorts reported in our study with the previous reports on concussed ice-hockey players25 and military personnel26 is not possible.
Recent studies35-37 have examined the use of blood biomarkers, which included ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP), for the diagnosis and prognosis of TBI. Each of these biomarkers was effective alone and, in 1 study,35 more specific and sensitive when combined in diagnosing TBI. However, a potential limitation of these studies is the short half-lives of UCH-L1 (<12 hours) and GFAP (<2 days) combined with the sensitivity limits of currently available assays.36,38 P-tau and T-tau levels in cerebrospinal fluid have diagnostic value for identifying individuals with Alzheimer disease.39-41 However, detection of these proteins in blood have been challenging owing to their low levels, which may now be overcome by the availability of new high-sensitivity assay platforms (single molecule array and a-EIMAF).25-27
We also found that plasma P-tau levels and P-tau–T-tau ratio in patients with chronic TBI are significantly higher than in healthy controls (Figure 4). Chronic traumatic encephalopathy was first described in 1928 by Martland42 to describe the clinical tremors and impaired cognition that affected some boxers. Being “punch drunk” was later called “dementia pugilistica”7 and then refined as CTE.43,44 Patients with CTE show progressively worsening dementia, poor executive function, confusion, anxiety, depression, and irritability that appear years after the initial trauma events.45,46 Omalu and colleagues5,19 reported neuropathologic lesions consistent with CTE in the brain of an American football player and a professional wrestler. Although CTE is associated with a history of repetitive mTBI or concussion, it is possible that a single but significant TBI event could also lead to the initiation of a tau phosphorylation cascade similar to those observed in repetitive mTBI. Consistent with this, our study showed elevations of plasma P-tau and T-tau levels in both the acute and the chronic phases of TBI. If, in fact, the tau phosphorylation cascade extends from the acute post-TBI phase into the chronic phase, it is possible that, in vulnerable individuals or those who experience successive TBI events, there may be sufficient cumulative tauopathy to initiate and/or accelerate the development of CTE.
For detection of tauopathy in particularly vulnerable TBI cohorts (athletes and blast-exposed military), postmortem neuropathologic examination along with blood T-tau and P-tau level quantitation is ideal; however, conducting both is often infeasible. The development of specific tau tracers for positron emission tomographic imaging have enabled the analysis of the presence and intensity of tau pathology in patients suspected of having tauopathies.47 Thus, future studies correlating tau positron emission tomographic imaging data with the levels of P-tau and P-tau–T-tau ratios may offer a novel path for differential diagnosis, prognosis, and disease progression in patients with TBI.5,6,19
The fact that control samples were not collected at the study sites is a major limitation of the study. These commercially obtained control plasma samples had limited demographic and health status data of donors. Although all control and TBI patient samples collected for this study followed best practice guidelines, it is possible that the reliance on commercial control samples may have affected the comparisons between controls and patients with TBI due to possible differences in sample collection and processing. To address this limitation, we will further validate our T-tau and P-tau results using blood samples collected within 24 hours, at 1 to 2 weeks, and at 6 months after the TBI from approximately 1000 patients with TBI in the current TRACK-TBI study48 supplemented with 2 groups of controls: friends/family controls (n = 300) and non-TBI orthopedic injury controls (n = 300).36,49 Thus far, we were able to successfully contact and recruit a friend or family member for 92% of the case patients. This represented 46 friend controls and 54 family controls.
An additional limitation is that our study focused on a single P-tau epitope (P-Thr231). It will be important to examine other major P-tau epitopes. Follow-up studies should seek to examine the time course of the plasma or serum levels of P-tau vs T-tau in the same patients in a larger longitudinal cohort study.
Acute T-tau and P-tau level elevations occur not only in severe/moderate TBI, but also in patients with mTBI. We also identified the P-tau–T-tau ratio as an excellent biomarker index for TBI. We found that both acute P-tau levels and P-tau–T-tau ratio outperformed T-tau levels in discriminating by severity, CT abnormality, and outcome category. Finally, we report, for what we believe to be the first time, plasma P-tau level and P-tau–T-tau ratio elevations among patients with chronic TBI. Taken together, P-tau levels and P-tau–T-tau ratio might be useful biomarkers for both acute and chronic TBI.
Accepted for Publication: March 25, 2017.
Corresponding Author: Richard Rubenstein, PhD, Department of Neurology, SUNY Downstate Medical Center, 450 Clarkson Ave, PO Box 1213, Brooklyn, NY 11203 (email@example.com).
Published Online: July 24, 2017. doi:10.1001/jamaneurol.2017.0655
The TRACK-TBI Investigators are Shelly R. Cooper, BA; Kristen Dams-O’Connor, PhD; Allison J. Borrasso, MS; Tomoo Inoue, PhD, MD; Andrew I. R. Maas, PhD, MD; David K. Menon, PhD, MD; David M. Schnyer, PhD; Mary J. Vassar, RN, MS.
Affiliations of The TRACK-TBI Investigators: Brain and Spinal Injury Center, San Francisco General Hospital, San Francisco, California (Inoue, Vassar); Department of Neurological Surgery, University of California, San Francisco (Inoue, Vassar); Department of Neurosurgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Borrasso); Department of Rehabilitation Medicine, Icahn School of Medicine at Mount Sinai, New York, New York (Dams-O’Connor); Department of Psychology, Washington University, St Louis, Missouri (Cooper); Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium (Maas); Departments of Anesthesia and Neurocritical Care, University of Cambridge, Cambridge, England (Menon); Department of Psychology, University of Texas, Austin (Schnyer).
Author Contributions: Drs Rubenstein and Wang had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Manley and Wang shared co-senior authorship.
Study concept and design: Rubenstein, Winkler, Diaz-Arrastia, Gordon, Okonkwo, Davies, Agarwal, Manley, Wang.
Acquisition, analysis, or interpretation of data: Rubenstein, Chang, Yue, Chiu, Winkler, Puccio, Diaz-Arrastia, Yuh, Mukherjee, Valadka, Lin, Sarkis, Yang, Manley, Wang.
Drafting of the manuscript: Rubenstein, Chang, Yue, Chiu, Winkler, Agarwal, Sarkis, Wang.
Critical revision of the manuscript for important intellectual content: Rubenstein, Yue, Winkler, Puccio, Diaz-Arrastia, Yuh, Mukherjee, Valadka, Gordon, Okonkwo, Davies, Lin, Yang, Manley, Wang.
Statistical analysis: Yue, Winkler, Diaz-Arrastia, Lin, Sarkis, Yang, Manley.
Obtained funding: Rubenstein, Diaz-Arrastia, Valadka, Gordon, Okonkwo, Manley, Wang.
Administrative, technical, or material support: Rubenstein, Chang, Chiu, Puccio, Mukherjee, Okonkwo, Davies, Agarwal, Lin, Yang, Manley.
Study supervision: Rubenstein, Diaz-Arrastia, Okonkwo.
Conflict of Interest Disclosures: Dr Wang holds stock in Banyan Biomarkers Inc. No other disclosures were reported.
Funding/Support: This study was supported in part by the Office of the Assistant Secretary of Defense for Health Affairs through the Department of Defense (DOD) Broad Agency Announcement under award numbers W81XWH-11-2-0069 (Dr Rubenstein) and W81XWH-14-2-0166 (Dr Rubenstein). It was also supported in part by National Institutes of Health (NIH) grant RC2 NS069409 (Dr Manley), NIH grant 1U01 NS086090-01 (Dr Manley), US DOD grant W81XWH-14-2-0176 (Dr Manley), US DOD grant W81XWH-13-1-04 (Dr Manley), NIH grant R21NS085455-01 (Dr Wang), and University of Florida McKnight Brain Institute BSCIRTF fund (Dr Wang).
Role of the Funder/Sponsor: The NIH and DOD had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Opinions, interpretations, conclusions, and recommendations are those of the authors and are not necessarily endorsed by the DOD.